Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Center, Phase I Clinical Study to Evaluate the Safety of MASCT-I Combined With PD1 Antibody in Vivo for the Advanced Soild Tumor Including Gastric Cancer，Triple-negative Breast Cancer and Ovarian Cancer

NCT03393416 is registered in ClinicalTrials.gov with HRYZ Biotech Co. as lead sponsor.

NCT NCT03393416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03393416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Center, Phase I Clinical Study to Evaluate the Safety of MASCT-I Combined With PD1 Antibody in Vivo for the Advanced Soild Tumor Including Gastric Cancer，Triple-negative Breast Cancer and Ovarian Cancer
Lead sponsor
HRYZ Biotech Co.
Phase
Phase 1
Overall status
Unknown status
Start date
April 19, 2018
Completion date
July 31, 2020
Enrollment
28 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer